Table 4 Comparison between factors and occurrence of adverse reactions, drug choice problems, and dosing problems

11 (44.0)

74 (42.3)

> 0.999^a

28 (36.8)

87 (70.2)

< 0.001^a*

34 (61.8)

81 (70.4)

0.548^a

14 (56.0)

101(57.7)

48 (63.2)

37 (29.8)

21 (38.2)

64 (29.6)

19 (76.0)

134 (76.6)

> 0.999^a

60 (78.9)

93 (75.0)

0.640^a

38 (69.1)

115 (79.3)

0.182^a

6 (26.0)

41 (23.4)

16 (21.1)

31 (25.0)

17 (30.9)

30 (20.7)

17 (68.0)

126 (72.0)

0.859^a

45 (59.2)

98 (79.0)

0.004^a*

40 (72.7)

103 (71.0)

0.951^a

8 (32.0)

49 (28.0)

31 (40.8)

26 (21.0)

15 (27.3)

42 (29.0)

17 (68.0)

107 (61.1)

0.660^a

53 (69.7)

71 (57.3)

0.106^a

40 (72.7)

84 (57.9)

0.078^a

8 (32.0)

68 (38.9)

23 (30.3)

53 (42.7)

15 (27.3)

61 (42.1)

12 (48.0)

109 (62.3)

0.193^b

47 (61.8)

74 (59.7)

0.877^a

36 (65.5)

85 (58.6)

0.471^a

13 (52.0)

66 (37.7)

29 (38.2)

50 (40.3)

19 (34.5)

60 (41.4)

12 (48.0)

88 (50.3)

> 0.999^a

46 (60.5)

54 (43.5)

0.029^a*

35 (63.6)

65 (44.8)

0.027^a*

13 (52.0)

87 (49.7)

30 (39.5)

70 (56.5)

20 (36.4)

80 (55.2)

1 (4.0)

10 (5.7)

> 0.999^b

6 (7.9)

5 (4.0)

0.399^a

5 (9.1)

6 (4.1)

0.306^a

24 (96.0)

165 (94.3)

70 (92.1)

119 (96.0)

50 (90.9)

139 (95.9)

7 (28.0)

57 (32.6)

0.819^a

17 (22.4)

47 (37.9)

0.033^a*

15 (27.3)

49 (33.8)

0.476^a

18 (72.0)

118 (67.4)

59 (77.6)

77 (62.1)

40 (72.7)

96 (66.2)